Etamicastat

• UNSPSC Description:

  Etamicastat (BIA 5-453) is a potent and reversible dopamine-β-hydroxylase (DBH) inhibitor with an IC50 value of 107 nM[1]. Etamicastat can be used in the research of cardiovascular diseases[2].

• Target Antigen:

  Dopamine β-hydroxylase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Etamicastat.html

• Solubility:

  10 mM in DMSO

• Smiles:

  S=C1NC=C(CCN)N1[C@H]2COC3=C(C=C(F)C=C3F)C2

• Molecular Weight:

  311.35

• References & Citations:

  [1]Loureiro AI, et al. Etamicastat, a new dopamine-ß-hydroxylase inhibitor, pharmacodynamics and metabolism in rat. Eur J Pharmacol. 2014 Oct 5;740:285-94.|[2]ManuelVaz-da-Silva, et al. Cardiac safety profile of etamicastat, a novel peripheral selective dopamine-β-hydroxylase inhibitor in non-human primates, human young and elderly healthy volunteers and hypertensive patients. IJC Metabolic & Endocrine. 2015 Jun; (7): 10-24

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  760173-05-5